Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Clin Cancer Res. 2012 Oct 23;18(24):6784–6791. doi: 10.1158/1078-0432.CCR-12-1785

Table 1.

Characteristics of HER2+ tumors recurring on or after trastuzumab therapy

n = 63
Therapeutic regimen
Only adjuvant trastuzumab 21
Several lines of chemotherapy 42
Metastatic tissue site
Ipsilateral breast/axilla/chest wall 39 (62%)
Bone 1 (2%)
Liver 13 (21%)
Lung 4 (6%)
Brain 6 (9%)